about
Molecular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Onco-Hematology.Hemophilia Care in the Pediatric Age.p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytesFanconi anemia patients are more susceptible to infection with tumor virus SV40Paroxysmal nocturnal hemoglobinuria clones in children with acquired aplastic anemia: a multicentre study.Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia.TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells.Human Fanconi A cells are susceptible to TRAIL-induced apoptosis.TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro.Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience.Impaired immune response to Candida albicans in cells from Fanconi anemia patients.High frequency of ribosomal protein gene deletions in Italian Diamond-Blackfan anemia patients detected by multiplex ligation-dependent probe amplification assay.Etanercept as a salvage treatment for refractory aplastic anemia.Severe lactic acidosis due to thiamine deficiency in a patient with B-cell leukemia/lymphoma on total parenteral nutrition during high-dose methotrexate therapy.Fanconi anaemia: new strategies.Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants.Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up.NOLA1 gene mutations in acquired aplastic anemia.Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children.Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia.Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP).Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian populationp38 Mitogen-activated protein kinase inhibition enhances in vitro erythropoiesis of Fanconi anemia, complementation group A-deficient bone marrow cells.Clinical aspects of Fanconi anemia individuals with the same mutation of FANCF identified by next generation sequencing.The polymorphisms -318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian populationSomatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian AInterferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemiaGilbert syndrome as differential diagnosis of hyperbilirubinemia in acquired aplastic anemiaEtanercept treatment in Fanconi anaemia; combined US and Italian experience
P50
Q33695948-C29A9A2C-378B-4694-A8C2-4AEA0BC3E3A6Q33737259-9D488DCA-4BC7-4BB1-9984-15C66E300128Q34123342-1EEFE614-9CFF-43BF-ACF4-EC5901286F76Q35048631-EFF33508-4596-47F9-A166-DC04726CEF85Q35203888-B33FDA6B-3837-4386-9EFC-FAEA7E28BEE1Q37470945-BAA835EE-038C-43A0-927F-6C819C7196CBQ37484487-667A514F-08A7-458C-98B1-57FE914BEB96Q40181983-F8C85503-9C35-4924-A589-A9FC440E2AA6Q40647455-1BC4D67F-254F-45DF-86B1-A93AF3D8B750Q41172796-2A8231DC-CBDF-4D8F-9C16-68CB7CE8A81BQ41432223-21351224-E4C1-4AEE-B30F-EADB0FC79F95Q41528346-B7DF1851-E61A-4579-9F7A-4C1D4BA5CF16Q44592963-3BABE8C0-685C-48FE-ACE0-6E195BB05045Q44685201-FA90AAA8-7245-4F57-9522-DEB127800BE5Q45878350-8FF65A58-2BB1-4909-A4E3-7D60E6E3B599Q46126217-A8AFF4A5-7160-4326-B991-131429EF7961Q46824421-F157D34F-EF8E-459C-93D6-37B2EA589A37Q48072413-602FA77D-2127-48A2-A00B-2848FD86617FQ50467512-81A94756-41DD-4B4D-8B49-0DD5C22921F7Q50492335-972274A8-0203-4DC1-BC7D-FF5C0FF2944FQ52943278-85EA55E8-5058-430A-9C0C-8EE411C596E1Q54265992-D9FD0D48-6C54-45E4-96AA-37E400CF460DQ54300487-452B52F6-43F8-463A-9A48-D9040DB01CB5Q55059137-84AB5AE4-9EE3-47BB-9EEC-78EB0847DAAEQ56902970-ECBEAA88-1688-4419-9D85-9CE5C73CEC2EQ57943230-F6CF1039-998C-4220-BF90-2101A64C5BCEQ77637215-EDED097F-5294-4F74-9794-AF489773160CQ80811226-32F29F40-D985-4133-8076-AD825A056022Q84627878-A671B3FB-4977-484E-8433-78F592126AED
P50
description
researcher ORCID ID = 0000-0002-7135-9171
@en
wetenschapper
@nl
name
Johanna Svahn
@ast
Johanna Svahn
@en
Johanna Svahn
@es
Johanna Svahn
@nl
type
label
Johanna Svahn
@ast
Johanna Svahn
@en
Johanna Svahn
@es
Johanna Svahn
@nl
prefLabel
Johanna Svahn
@ast
Johanna Svahn
@en
Johanna Svahn
@es
Johanna Svahn
@nl
P108
P1153
55916592500
P21
P31
P496
0000-0002-7135-9171